BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-590@pharmaconomics
DTSTAMP:20260707T034712Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:TRVI Phase 2 — Haduvio (estimated date)
DESCRIPTION:Phase 2 trial results for Haduvio in non-IPF ILD-related chronic cough are due ~ Dec 31\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1563880/000119312526206382/trvi-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/590
URL:https://www.pharmaconomics.com/e/590
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TRVI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR